 Home > Medical News > Medicines Company News > $900 million to help develop CRISPR gene editing therapy Vertex renews cooperation

$900 million to help develop CRISPR gene editing therapy Vertex renews cooperation

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

fast clotting blood

blood human body

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Vertex Pharmaceuticals and CRISPR Therapeutics announced that the two companies have renewed their cooperation agreement for the joint development of the treatment CTX001 under investigation.

CRISPR-Cas9 gene editing technology uses artificially designed guide RNA (guide RNA) to identify the target genome sequence, guide Cas9 protease to effectively cut DNA double strands, and modify genes through repair or recombination after DNA double strand breaks.

CTX001 has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of TDT and SCD by the US FDA, as well as fast track and orphan drug designation.

According to the revised terms of the agreement, Vertex will lead the global development, production and promotion of CTX001 with the support of CRISPR Therapeutics to maximize the potential of CTX001 to change the lives of tens of thousands of patients.

Reference materials:

[1] Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.